Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress, ELCC, 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa in combination with MSD’s (MRK) anti-PD-1 KEYTRUDA and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer. The global trial will enrol approximately 750 patients regardless of PD-L1 expression and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Reports Increased Revenue Amid Growing R&D Costs
- Immutep Reports Increased Revenue Amid Rising R&D Costs
- Immutep Advances to Phase III with Key Approvals and Promising Trial Results
- Immutep promotes Christian Mueller to CDO, CMO Florian Vogl to depart
- Immutep reports Q2 cash receipts from customers A$8,000
Questions or Comments about the article? Write to editor@tipranks.com